Filter By Category
Archives
Share on -
AZINTUXIZUMAB
Generic Name: AZINTUXIZUMAB
ABSTRACT -
Azintuxizumab refers to the monoclonal antibody component used in the antibody-drug conjugate azintuxizumab vedotin. It targets CS1, also known as SLAMF7 or CD319, a cell-surface glycoprotein expressed on multiple myeloma cells and immune subsets. As a monoclonal antibody, it has a defined protein sequence rather than a small-molecule chemical skeleton. Development/regulatory status: Investigational antibody component; most described as part of azintuxizumab vedotin.
This document is for structured API information only. It is not a prescribing guide. Clinical use, if any, must follow the approved local label, trial protocol, and specialist medical supervision.
DOSAGE-
- No approved standalone routine dosing schedule is established.
- Any administration would be protocol-defined and likely by intravenous infusion.
- Dose, premedication, and infusion duration depend on the investigational product, antibody format, and trial design.
- Do not use outside regulated clinical research or an approved specialist setting.
SIDE EFFECTS-
Possible side effects and safety concerns include:
- Infusion-related reactions such as fever, chills, hypotension, or rash
- Fatigue, nausea, headache, or flu-like symptoms
- Cytopenias or infection risk in oncology patients
- Immune-mediated reactions or laboratory abnormalities
- Hypersensitivity including rare anaphylaxis
ALLERGIC REACTIONS -
Hypersensitivity to azintuxizumab or related compounds/products may occur. Symptoms may include:
- Infusion reaction or injection-site reaction where applicable
- Rash or urticaria
- Bronchospasm or breathing difficulty
- Facial, lip, tongue, or throat swelling
- Anaphylaxis
Important: Patients who develop an allergic reaction to azintuxizumab should seek immediate medical attention and inform all future healthcare providers of the allergy.
DRUG INTERACTIONS-
- Other monoclonal antibodies, immunotherapies, chemotherapy, or corticosteroids may alter toxicity or response.
- Live vaccines may be inappropriate during immune suppression.
- Myelosuppressive medicines can increase cytopenia risk.
- Patients should disclose all medicines, vaccines, supplements, and investigational agents.
PREAUTIONS–
- Administer in a setting equipped for infusion reactions.
- Monitor vital signs, blood counts, infection signs, and immune-mediated toxicity.
- Use caution in active infection, severe immune compromise, pregnancy, or lactation.
WARNINGS –
- Monoclonal antibodies can cause serious infusion and hypersensitivity reactions.
- Seek urgent care for breathing difficulty, facial swelling, severe rash, or hypotension.
- Keep out of reach of children.
Share on -
. Developed by